A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.
Status:
Not yet recruiting
Trial end date:
2025-12-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn about the effects of Rimegepant to help prevent
migraine.
This study is seeking for participants who:
- Are male and female of 18 years of age or older.
- Have at least 1 year history of migraine .
- Did not take any medication for migraine before the start of this study. The study will
go on for around 30 weeks, including 4 Phases and 11 Visits. Participants who are
selected for the study will be randomly assigned to treatment groups. After which, the
participants will enter a 12-week Double-blind Treatment (DBT) Phase. After finishing
the DBT Phase, some selected participants may enter a 12-week Open-label Extension (OLE)
Phase. Participants will come back to the study site at the end of Week 24 for the End
of Treatment (EOT) Visit. There will be a follow-up Week 2 Visit around 14 days after
the EOT visit.
Participants will be asked to take 1 tablet of study medicine every other calendar day. This
need to be followed regardless of whether they have a migraine on that day or not. During the
OLE Phase only, if a participant has a migraine on a non-scheduled dosing day, they may take
1 tablet of Rimegepant orally disintegrating tablet (ODT) as acute treatment for their
migraine, if needed, with a maximum of 1 tablet of Rimegepant per calendar day. The study
team will look at how each participant is doing with the study treatment during the regular
visits at the study clinic.